MaxCyte, Inc. (MXCT) Return on equity 2019–2025
MaxCyte, Inc. (MXCT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-26.0%FY2025 · since FY2019: -94.8% → -26.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -26.0% | -6.1 pp |
| FY2024 | -19.9% | -3.6 pp |
| FY2023 | -16.3% | -7.1 pp |
| FY2022 | -9.3% | -2.0 pp |
| FY2021 | -7.3% | +28.3 pp |
| FY2020 | -35.6% | +59.2 pp |
| FY2019 | -94.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice